



(51) International Patent Classification:

A61K 31/713 (2006.01) A61K 47/60 (2017.01)
A61K 47/54 (2017.01) A61K 47/64 (2017.01)
A61K 47/56 (2017.01) C12N 15/113 (2010.01)

(21) International Application Number:

PCT/US2021/058232

(22) International Filing Date:

05 November 2021 (05.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/110,837 06 November 2020 (06.11.2020) US

(71) Applicants: **ARBUTUS BIOPHARMA CORPORATION** [CA/CA]; 100-8900 Glenlyon Parkway, Burnaby, British Columbia V5J 5J8 (CA). **ARBUTUS BIOPHARMA, INC.** [US/US]; 701 Veterans Circle, Warminster, Pennsylvania 18974 (US).

(72) Inventors; and

(71) Applicants: **DALY, Owen M.** [IE/US]; 701 Veterans Circle, Warminster, Pennsylvania 18974 (US). **LEE, Amy C. H.** [CA/CA]; 701 Veterans Circle, Warminster, Pennsylvania 18974 (US). **SOFIA, Michael J.** [US/US]; 701 Veterans Circle, Warminster, Pennsylvania 18974 (US). **THI, Emily P.** [CA/US]; 701 Veterans Circle, Warminster, Pennsylvania 18974 (US).

(74) Agent: **MALEN, Peter L.** et al.; VIKSNINS HARRIS PADYS MALEN LLP, 7900 International Drive, Suite 410, Bloomington, MN 55425 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: TARGETED CONJUGATES COMPRISING MODIFIED SIRNA

Figure 4.



(57) Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, an siRNA, and optional linking groups. The conjugates are useful to target siRNA.